Inventiva S.A Market Cap ($812.04 Million)
Market Cap & Net Worth: Inventiva S.A (IVA)
Inventiva S.A market cap. Inventiva S.A (PA:IVA) has a market capitalization of $812.04 Million (€694.58 Million) as of October 30, 2026. Listed on the PA stock exchange, this France-based company holds position #9545 globally and #150 in its home market, demonstrating a 7.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inventiva S.A's stock price €3.35 by its total outstanding shares 207647924 (207.65 Million).
Inventiva S.A Market Cap History (2017–2026)
Inventiva S.A market cap history from 2017 to 2026. Data shows change from $1.20 Billion to $812.04 Million (-9.25% CAGR). Check Inventiva S.A stock quote for real-time trading data and today's change.
Index Memberships
Inventiva S.A is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$222.38 Billion | 0.37% | #56 of 119 |
|
CAC Small90
CACS
|
$35.99 Billion | 2.26% | #12 of 64 |
|
CAC All-Tradable
CACT
|
$2.80 Trillion | 0.03% | #114 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.80 Trillion | 0.03% | #114 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.80 Trillion | 0.03% | #114 of 179 |
|
CAC Health Care
FRHC
|
$259.95 Billion | 0.31% | #12 of 36 |
Weight: Inventiva S.A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Inventiva S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inventiva S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Inventiva S.A (IVA) cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
213.63x
Inventiva S.A's market cap is 213.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.20 Billion | $6.52 Million | -$17.23 Million | 184.28x | N/A |
| 2018 | $1.36 Billion | $3.20 Million | -$33.62 Million | 426.75x | N/A |
| 2019 | $890.94 Million | $7.00 Million | -$30.22 Million | 127.31x | N/A |
| 2020 | $2.85 Billion | $372.00K | -$31.62 Million | 7648.32x | N/A |
| 2021 | $2.85 Billion | $4.19 Million | -$49.64 Million | 679.55x | N/A |
| 2022 | $1.09 Billion | $12.18 Million | -$54.27 Million | 89.20x | N/A |
| 2023 | $994.11 Million | $17.48 Million | -$110.43 Million | 56.88x | N/A |
| 2024 | $529.22 Million | $14.72 Million | -$184.21 Million | 35.94x | N/A |
| 2025 | $957.70 Million | $4.48 Million | -$354.14 Million | 213.63x | N/A |
Competitor Companies of IVA by Market Capitalization
Companies near Inventiva S.A in the global market cap rankings as of October 30, 2026. See Inventiva S.A net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Inventiva S.A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Inventiva S.A (2017–2026)
Market capitalization of Inventiva S.A from 2017 to today. Between 2017 and today, Inventiva S.A's market cap moved from $1.20 Billion to $ 812.04 Million, with a yearly change of -9.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €812.04 Million | -15.21% |
| 2025 | €957.70 Million | +80.96% |
| 2024 | €529.22 Million | -46.76% |
| 2023 | €994.11 Million | -8.49% |
| 2022 | €1.09 Billion | -61.88% |
| 2021 | €2.85 Billion | +0.17% |
| 2020 | €2.85 Billion | +219.35% |
| 2019 | €890.94 Million | -34.70% |
| 2018 | €1.36 Billion | +13.54% |
| 2017 | €1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Inventiva S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $812.04 Million USD |
| MoneyControl | $812.04 Million USD |
| MarketWatch | $812.04 Million USD |
| marketcap.company | $812.04 Million USD |
| Reuters | $812.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more